The OX1R antagonist SB334867 had no effect on OxA-induced inhibition, which is likely to occur via a neuronal and/or endocrine OX2R. On the other hand, SB334867 induced a significant right shift of the concentration-effect curve for OxB. This OxBpreferring OX1R pathway was not sensitive to TTX or to CCKR antagonists, suggesting that OxB may act directly on enterocytic OX1R. These distinct effects of OxA and OxB are consistent with the expression of OX1R and OX2R mRNA in the epithelial and non-epithelial tissues, respectively. Our data delineate a new function for orexins as inhibitors of intestinal glucose absorption and provide a new basis for orexin-induced short-term control of energy homeostasis. Orexins/hypocretins are peptides discovered by orphan receptor technologies (1) or subtractive cDNA cloning (2) . The two orexins, A and B, are encoded by a single gene and are derived from a common prepro-orexin that is processed into the 33-amino acid orexin-A (OxA) and the 28-amino acid OxB. These peptides share 46% amino acid identity in rat (3) . Orexins are neuropeptides present in the hypothalamic neurons that project throughout the central nervous system (CNS) to nuclei involved in the control of feeding, sleep-wakefulness, neuroendocrine homeostasis and autonomic regulation (1; 3). Two orexin receptor subtypes, OX1R and OX2R (1; 2), are serpentine G protein-coupled receptors that bind both orexins. As shown in rat, OX2R binds OxA and OxB with equal affinity whereas OX1R has a preference for OxA (1; 3). Both receptors appear to be coupled to calcium mobilisation (1; 3). As with other peptides found in the hypothalamic area (ie. PYY, NPY, leptin, ghrelin, galanin) belonging to the so-called brain-gut axis, expression of orexins has also been reported in enteric neurons and endocrine cells of the digestive tract (4; 5) . OxA was demonstrated to trigger cholecystokinin (CCK) release in STC-1 cells, an intestinal neuroendocrine cell model that expresses OX1R and OX2R (6) . These studies, together with those characterising the orexin receptors in the enteric nervous system, pancreas and intestinal mucosa cells (4; 5; 7), suggest that orexins can exert direct control on gut functions.
The hypothalamus has been the focus of considerable attention regarding its role in the regulation of energy homeostasis, but the gut is now also considered as a major player in the regulation of food intake. To achieve energy homeostasis, the CNS integrates signals coming from the peripheral organs that provide information about the level of energy fluxes and stores through neuronal pathways. Primary input is mediated by signal molecules conveyed in the intestinal lumen. Glucose, the major form of absorbed carbohydrate, is also an important signal molecule. Glucose levels in the bloodstream are critically evaluated by integrated hypothalamic circuits of neurons and neurochemicals that regulate appetite, energy expenditure and metabolism. Orexin neurons have been recently identified to play a major role in this regulation (8) (9) (10) . Orexin glucosensing neurons can modulate their intrinsic electrical activity according to the ambient fluctuations in the levels of nutrients and appetiteregulating hormones, and are believed to translate directly rises and falls in body energy levels into different states of consciousness (10) .
Following a meal, exogenous glucose is rapidly transported from the lumen of the small intestine into the blood stream and tissues. The first step of this process is the intracellular accumulation of glucose in enterocytes by the sodium-dependent glucose transporter 1, SGLT1. Intracellular glucose is then released into the interstitial space and blood via the GLUT2 glucose transporter located in the basolateral membrane. The activity of SGLT1 is highly regulated by hormones and intestinal peptides (11) (12) (13) (14) (15) indicating that control of intestinal glucose entry is crucial in the maintenance of energy homeostasis. Indeed, expression of SGLT1 is dramatically increased in diabetic humans (16) . Although orexins and their receptors Response' curves to orexins were studied non-cumulatively. OIsc response to carbachol (100 µmol/l) was used at the end of the experiment as a control.
Epithelial cell isolation and RT-PCR analysis
Epithelial and non epithelial cellular fractions of rat jejunum were obtained from everted jejunum shaken in a dispersing solution containing EDTA as described in detail previously (17; 18). Non-epithelial tissues were obtained after complete removal of epithelial cells. (Fig. 1) . Areas under the curve (AUC)
were significantly decreased for both OxA and OxB as compared to control (Fig. 1,   inset ). Altogether, these data indicate that peripherally administered OxA and OxB can reduce intestinal absorption of glucose in a glucose tolerance test. When glucose is given luminally, the OGTT is an index of intestinal glucose entry through the glucose transporter SGLT-1 (19) . Therefore, we further examined in vitro the effect of orexins on active intestinal absorption of glucose. for OxA and B respectively (57 and 50.7% inhibition respectively). We then studied dose-effect of OxA and OxB. As shown in Figure 2B , maximal effects of OxA and OxB were observed at 100 nmol/l peptide concentration and represented a ~70% inhibition of glucose-induced Isc. The IC50 values for OxA and OxB were 0.9 and 0.4 nmol/l, respectively. To analyse the pathways involved in this inhibition, we examined the effect of the OX1R antagonist SB334867. The response to OxA was not significantly modified by SB334867 (Fig. 3A) . In sharp contrast, the Ox1R antagonist markedly shifted to the right the dose-response curve to OxB (Fig. 3B ). This clearly indicates that the effect of OxB involves an OX1 receptor whereas the effect of OxA is mostly independent of the OX1 receptor. In the absence of available OX2R antagonist, we could not further explore the orexin receptor mediating the effect of OxA. OxA action is not mediated by the OX1R (see Fig. 3A ), it is likely that it involves the other orexin receptor, i.e. OX2R. This is in agreement with our finding that a specific OX2R agonist triggers an inhibition of glucose absorption (Fig. 6 ). In line with the effect of TTX on OxA-induced inhibition, the effect of the OX2R agonist was sensitive to TTX. Also in accordance with the involvement of CCK2R in this pathway, (Fig.6 ).
Intestinal glucose transport in vitro is

Analysis of the pathway involved in the inhibitory
Analysis of OXRs mRNA distribution in jejunal mucosa
Finally, RT-PCR analysis of OxRs in rat jejunal mucosa showed the expression of OX 1 R in epithelial cells (Fig 7; lane 5) but not in non-epithelial fraction (Fig 7; lane 7) , in line with our functional results. In contrast, OX 2 R was found essentially in nonepithelial fraction (Fig 7; lane 7) , a localization in good agreement with the expression of OX 2 R in neurons. A small amplicon was also found in the epithelial fraction, possibly corresponding to the presence of OX 2 R in enteroendocrine cells (Fig 7; lane   5 ). (25) , indicating that changes in circulating glucose concentration can activate orexin neurons. OxA secretion from the endocrine pancreas is also stimulated by low glucose levels (7). Our finding that orexin A and B can induce a short-term modulation of the incoming flux of glucose gives a new insight into the involvement of orexins in glucose regulation.
We found that both orexins reduced significantly blood glucose when administered by i.p. route. In previous studies, it was found that OxA, when given I.V., had no (12) or an increase (i.e. adenosine (27) , EGF (13) (Figure 8; pathway 2) . This is consistent with a previous report on neuroendocrine STC-1 cells, which express OX2R and release CCK in response to orexin A (6). Third, OxA could also directly activate efferent CCKreleasing neuronal cells via OX2R (Figure 8 ; pathway 3). Such efferent CCK cells have been described in submucosal networks of enteric neurons (30) . In our scheme, these pathways are not mutually exclusive. In all cases, CCK released by endocrine I cells is certainly a major mediator of OxA action in the inhibition of SGLT-1 activity.
However, the fact that the action of OxA is not completely inhibited by the CCKR antagonist cocktail (Fig. 4C) suggests the possible involvement of minor mediators in this action, the nature of which remains to be established. Here, we further demonstrate that this CCK-mediated effect of OxA involved a CCK2R subtype. This finding is in agreement with previous data showing that inhibition by leptin of glucose absorption in rat jejunum is mediated by CCK (11).
Conversely, our data indicate that OxB produced and secreted by neuronal cells in the mucosa could directly activate the OX1R on enterocytes (Figure 8; pathway 4) . (23) . We propose that orexins released by neurons and endocrine cells in the gut, and acting via distinct pathways, are connected to glucose transporter activity to allow sensing and control of incoming levels of glucose (as a part of a glucose "sensing" cell network that includes the pancreatic cells (7) and duodenal SGLT-3 sensing (33)). Modulation of glucose levels through this postulated loop, in close relationship with other hormones and neuropeptides (i.e. leptin, CCK, ghrelin), could in turn result in an increase in neuronal activity (32) and in production/secretion of peripheral orexin (7). In addition, they suggest that orexins are also involved in a regulatory loop between enteric glucose entry and central evaluation of peripheral available energy levels, enlarging the group of gut peptides involved in energy homeostasis (34) . Further studies are needed to evaluate this possible role of orexins in pathologies associated with anomalies in energy homeostasis including obesity and diabetes. (1 nmoles/l). n= 5-7; *, P<0.05 vs control. 
